Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment for women news

Show

From To
Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

Published
05 October 2018
From
IDSA press release
Developmental problems of children born to women with HIV linked to substance use and HIV, not antiretrovirals

Pre-term births and developmental problems in children born to mothers with HIV are associated with HIV infection, substance use and smoking, Canadian researchers have reported in

Published
11 September 2018
By
Keith Alcorn
Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant

Lynn Mofenson, M.D., who is a researcher with the Elizabeth Glaser Pediatric AIDS Foundation, explains what is known about the potential risk of neural tube defects when dolutegravir is used around the time of conception.

Published
15 August 2018
From
The Body PRO
Dolutegravir: update on infant neural tube defects from Botswana

Dolutegravir treatment at the time of conception is associated with a higher risk of neural tube defects in infants exposed to the drug when compared

Published
24 July 2018
By
Keith Alcorn
Dolutegravir-based ART recommended for all – if reliable contraception is available

The World Health Organization (WHO) has issued new antiretroviral treatment guidelines recommending dolutegravir-based treatment as the preferred first-line treatment option for all adults, adolescents and children, including

Published
24 July 2018
By
Keith Alcorn
FDA says Prezcobix should not be given to pregnant women

Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.

Published
11 June 2018
From
Healio (requires free registration)
BHIVA statement on Potential Safety Signal in Infants Born to Women Conceiving on Dolutegravir

The BHIVA HIV in Pregnancy Guidelines Writing group makes the following recommendations: all women wishing to conceive should be started on folic acid 5mg OD regardless of their cART regimen; all women commencing DTG should have a negative pregnancy test prior to initiation and ongoing method of contraception documented; we advise a review of all patient records of women aged up to 50yo on DTG with regards to conception plans, documented method of contraception and current pregnancy status; we recommend that women at risk of pregnancy be contacted by their clinic to discuss the DTG safety report, which should be clearly documented, and the woman seen in person if pregnant.

Published
23 May 2018
From
British HIV Association
Dolutegravir may cause birth defects, European Medicines Agency warns

Regulatory agencies in the United States and European Union have warned that women with HIV who can become pregnant should not use the integrase inhibitor

Published
21 May 2018
By
Keith Alcorn
Potential safety issue affecting women living with HIV using dolutegravir at the time of conception

WHO advises that countries and ministries follow the existing 2016 WHO Consolidated ARV Guidelines, and consider the following: Pregnant women who are taking DTG should not stop their ARV therapy and should speak with their health provider for additional guidance. If other first‐line ARVs cannot be used in women of childbearing age, DTG may be considered in cases where consistent contraception can be assured.

Published
21 May 2018
From
World Health Organization
High prevalence of menopausal symptoms in women living with HIV, but very few receive treatments for them

Nine in ten women living with HIV aged 45 to 60 have hot flushes and other somatic symptoms of the menopause, but often have difficulties getting advice

Published
17 May 2018
By
Roger Pebody
← First12345...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.